Ghosh Rinko 4
4 · NEKTAR THERAPEUTICS · Filed Feb 10, 2012
Insider Transaction Report
Form 4
Ghosh Rinko
SVP & Chief Business Officer
Transactions
- Award
Stock Option
2012-02-08$7.21/sh+50,000$360,500→ 50,000 totalExercise: $7.21Exp: 2020-02-07→ Common Stock (50,000 underlying) - Award
Stock Option
2012-02-08$7.21/sh+50,000$360,500→ 50,000 totalExercise: $7.21Exp: 2020-02-07→ Common Stock (50,000 underlying)
Footnotes (2)
- [F1]This stock option vests on a monthly pro-rata basis over a period of four (4) years from the grant date (February 8, 2012).
- [F2]This stock option is subject to both time-based vesting and performance-based vesting conditions, both of which must be met before the shares subject to the option become vested and exerciseable. The time-based vesting is on a monthly pro-rata basis over a period of four (4) years from the grant date (February 8, 2012). The performance-based vesting condition will be met only if Nektar (or a licensee) files a new drug registration with the FDA or the European Medicines Agency for a significant drug candidate program including, without limitation, the following: (1) NKTR-118 (an oral peripherally-acting opioid antagonist); (2) NKTR-102 (a topoisomerase I inhibitor); (3) NKTR-061/Amikacin Inhale (a drug-device combination for an inhaled solution of amikacin); or (4) BAX-855 (a longer-acting (PEGylated) form of a full-length recombinant factor VIII (rFVIII) protein).